AVIR vs RLAY

Analysts rate Relay Therapeutics, Inc.

(RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Relay Therapeutics, Inc.

(RLAY) delivered a total return of -57. 6%, compared to -74. 0% for Atea Pharmaceuticals, Inc. (AVIR). Over 10 years, the gap is even starker: RLAY returned -64. 3% versus AVIR's -81. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Atea Pharmaceuticals, Inc.

(AVIR) is the lower-risk stock at 1. 05β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 68% more volatile than AVIR relative to the S&P 500. On balance sheet safety, Atea Pharmaceuticals, Inc. (AVIR) carries a lower debt/equity ratio of 0% versus 6% for Relay Therapeutics, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Relay Therapeutics, Inc.

grew EPS 31. 8% year-over-year, compared to 3. 0% for Atea Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Atea Pharmaceuticals, Inc.

(AVIR) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVIR leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Atea Pharmaceuticals, Inc.

(AVIR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05)). Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVIR: -81. 7%, RLAY: -64. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AVIR is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.